coronavirus vaccination-Beijing 302 Hospital-COVID-19

This refers to a heterologous prime-boost SARS-CoV-2 vaccination strategy being evaluated in a Phase 1/2 clinical trial (NCT05273541) conducted by Beijing 302 Hospital. The regimen involves a heterologous prime-boost approach, where different types of COVID-19 vaccines (such as an inactivated vaccine followed by a booster of a different platform) are administered in sequence. This strategy is specifically being studied for its safety and immunogenicity in patients with various stable cancers, including breast cancer, hepatocellular carcinoma, lung cancer, esophageal cancer, gastric cancer, and colorectal cancer. The vaccination aims to induce a robust immune response against the SARS-CoV-2 spike protein to prevent COVID-19 infection and reduce disease severity in this vulnerable population.

Other names

prime-boost SARS-CoV-2 vaccinationheterologous prime-boost COVID-19 vaccinationcoronavirus vaccination